中新经纬7月10日电 10日晚顺鑫农业，万泰生物公告，预计上半年净利润同比减少八成以上。

　　公告显示，万泰生物预计2024年半年度归属于母公司所有者的净利润为2.4亿元至2.9亿元，与上年同期相比，将减少82.96%至85.90%。

来源：公告

　　对于业绩下降，万泰生物表示，疫苗板块主要产品二价HPV疫苗持续受九价HPV疫苗扩龄以及市场竞争、降库存等因素影响，销售收入及利润较去年同期回落。不过，诊断板块受益于流水线等相关大项目的加速推进，与全国300强医院的合作开展，剔除新冠诊断相关业务，诊断板块业务收入及利润维持一季度增速，总体运行平稳。

　　万泰生物还指出，预计第二季度营业收入为5.5亿元至6.8亿元，同比减少约46.75%至56.93%，与一季度降幅相比有所收窄。

　　资料显示，万泰生物是一家从事疫苗、体外诊断试剂和体外诊断仪器的研发、生产及销售的企业。

　　二级市场上顺鑫农业，受在研管线九价HPV疫苗等消息影响，万泰生物在2023年底股价持续飙升，进入2024年后持续回落。截至7月10日，公司股价年内跌超10%。(中新经纬APP)

","del":0,"gnid":"9faa51f3f110ca532","img_data":[{"flag":"2","img":[{"desc":"","height":"325","title":"","url":"http://p9.img.360kuai.com/t11508c75c8f2c970ef2e181679.jpg","width":"1080"},{"desc":"","height":"510","title":"","url":"http://p9.img.360kuai.com/t11508c75c8db875a6458942662.jpg","width":"628"}]}],"original":0,"pat":"art_src_1,fts0,sts0","powerby":"cache","pub_time":1720605450000,"pure":"","rawurl":"http://zm.news.so.com/44ec12d48ac58d159966838209de1ca1","redirect":0,"rptid":"72c0063a7adfc261","rss_ext":[],"s":"t","src":"中新经纬","tag":[{"clk":"keconomy_1:万泰生物","k":"万泰生物","u":""}],"title":"V观财报｜万泰生物预计上半年净利降超八成","type":"zmt","wapurl":"http://zm.news.so.com/44ec12d48ac58d159966838209de1ca1","ytag":"财经:金融证券:股票","zmt":{"brand":{},"cert":"中国新闻社旗下财经新媒官方账号","desc":"中国新闻社旗下财经新媒","fans_num":0,"id":"3377470056","is_brand":"0","name":"中新经纬","new_verify":"4","pic":"https://p0.img.360kuai.com/t0155517769ee80b417.jpg","real":1,"textimg":"https://p9.img.360kuai.com/bl/0_3/t017c4d51e87f46986f.png","verify":"0"},"zmt_status":0}","errmsg":"","errno":0}